What is the role of the intramembrane proteases in cancer? by Fluhrer, Regina & Schröder, Bernd
Despite significant efforts andachievements cancer still represents the second most
common cause of death in industri-
alised countries. Mutations and other
changes in the genome of cells induce
their malignant transformation which
leads to uncontrolled proliferation
and destructive growth. Survival, 
proliferation and migration of healthy
cells are controlled by an intricate 
network of signalling pathways. 
Dysregulation of such pathways is an
integral part of malignant transforma-
tion and contributes significantly to
the loss of growth control and the
ability to form metastases.
Intramembrane proteases are enzymes
that cleave substrate proteins embed-
ded in cellular membranes and
release the cleavage fragments from
the membrane (read more in the
October 2018 edition of Open Access
Government). By this, intramembrane
proteases actively control signalling
pathways as exemplified by the inten-
sively studied Notch pathway (read
more in the January 2019 edition of
Open Access Government). Following
activation of the Notch receptor by its
ligand, this receptor undergoes a
series of proteolytic cleavages culmi-
nating in the liberation of its intracel-
lular domain into the cytosol by
γ-secretase, an intramembrane pro-
tease, which is also involved in the
development of Alzheimer’s disease
(read more in the July 2019 edition of
Open Access Government). 
Over-activated Notch signalling plays
a well-established role in carcinogen-
esis and tumour progression. In certain
types of leukemia (T-ALL) over 50% of
cases exhibit Notch-activating muta-
tions which drive disease develop-
ment. Therefore, different means of
interfering with Notch signalling 
have been assessed. Pharmacological 
inhibition of γ-secretase blocks Notch
signalling since translocation of the
Notch intracellular domain to the cell’s
nucleus is dependent on cleavage of
Notch by γ-secretase. Therefore,
inhibitors of γ-secretase are evaluated
in promising phase I and phase II 
clinical studies against different solid
tumours and leukaemias. In particular,
patients with a documented activation
of the Notch signalling pathway in the
tumour may profit from such an
approach, possibly in conjunction with
established treatment strategies.
However, this approach may require
further evaluation, since beyond the
Notch receptor altogether more than
hundred different proteins have been
identified to be cleaved by γ-secre-
tase. Among these are also several
receptor tyrosine kinases, which can
support proliferation and survival of
cancer cells, but it is not clear yet if
inhibition of γ-secretase cleavage will
affect the signals induced by these
receptors and how this will impact on
tumour growth. Effects of these
receptors may also differ between
tumours of different origin and, thus,
will require further clinical studies. 
The reported anti-cancer action of
certain γ-secretase inhibitors may in
part also be supported by an accom-
panying action of these compounds
on members of a mechanistically
related protease family, the SPP/SPPL
proteases. Among these, in particular
Signal Peptide Peptidase (SPP) has
been linked with cancer. SPP was
found to be highly upregulated in lung
and breast tumours. In agreement,
SPP depletion significantly reduced
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cell growth and migration/invasion
capacity of tumour cells in animal
models. Since currently no specific
inhibitors of SPP suitable for in vivo
application are available, a potential
anti-cancer effect in humans remains
to be determined. With regard to the
underlying mechanisms, cleavage of
different substrate proteins has been
proposed to be responsible for the
tumour-promoting activity of SPP.
Therefore, further work will be
needed to unravel this proteolytic 
network and its role in cancer biology
as well as its therapeutic potential.
It is well established that a change of
glycosylation patterns can significantly
affect and modulate the behaviour of
cancer cells. Sugar moieties are
attached to almost half of all cellular
proteins during their synthesis by a
process known as protein glycosylation.
This is also the basis for formation of
the extracellular matrix, the material
surrounding our body cells constitut-
ing a scaffold for their growth and
migration. The extracellular matrix is
formed by secretion of various glyco-
proteins from cells. The adhesion of
cancer cells to this network as well as
the composition of the extracellular
matrix influence their potential to
metastasize. 
In this context, another member of
the SPP/SPPL protease family, SPPL3,
is of great interest to be explored, as
it is a major regulator of cellular 
protein glycosylation (read more in
the January 2019 edition of Open
Access Government) and, thus, also
impacts on the synthesis of the extra-
cellular matrix proteins. In this regard,
evaluating the impact of SPPL3 and a
modulation of its activity on tumour
cells is of great potential.
As these examples show, the role of
intramembrane proteases in cancer is
still emerging. These versatile enzymes
regulate central cellular pathways,
which also play a major role in tumour
cells. Whereas the assessment of the
therapeutic potential of γ-secretase
in clinical studies is already quite
advanced, our knowledge on other
intramembrane proteases in this 
context currently only results from
pre-clinical models or cell biological
studies. However, based on these
promising results it may be antici-
pated from further research efforts in
this direction that intramembrane
proteases will turn out to be attractive
targets in cancer therapy in the future.
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Impact of intramembrane proteases on cancer progression, 
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